TAC-101 (4-[3,5-bis(trimethylsilyl)benzamido]benzoic acid) inhibits spontaneous mediastinal lymph node metastasis produced by orthotopic implantation of Lewis lung carcinoma

Japanese Journal of Cancer Research

Volumn 90, Issue 11, 1999, Pages 1254-1261

  Murakami, Koji ^a,b   Yamaura, Takeshi ^a   Suda, Kazuhito ^a   Ohie, Shinji ^b   Shibata, Jiro ^b   Toko, Toshiyuki ^b   Yamada, Yuji ^b   Saiki, Ikuo ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

AP 1; LLC; Mediastinal lymph node metastasis; TAC 101; u PA

Indexed keywords

4 [3,5 BIS(TRIMETHYLSILYL)BENZAMIDE]; 4 [3,5 BIS(TRIMETHYLSILYL)BENZAMIDO]BENZOIC ACID; BENZOIC ACID DERIVATIVE; CISPLATIN; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; LEWIS CARCINOMA; LUNG PARENCHYMA; LYMPH NODE METASTASIS; MEDIASTINUM LYMPH NODE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

EID: 0032762592     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1999.tb00705.x     Document Type: Article

References (43)

1. Ginsberg, R. J., Vokes, E. E. and Raben, A. Cancer of the lung. In "Cancer: Principles and Practice of Oncology." 5th Ed., ed. V. T. Devita, Jr., S. Helman and S. A. Rosenberg, vol. 1, pp. 849-949 (1997). Lippincott-Raven, New York.
2. Regnard, J. F., Santelmo, N., Romdhani, N., Gharbi. N., Bourcereau, J., Dulmet, E. and Levasseur, P. Bronchioloalveolar lung carcinoma: results of surgical treatment und prognostic factors. Chest, 114, 45-50 (1998).
3. Vansteenkiste, J. F., Deleyn, P. R., Deneffe, G. J., Stalpaert, G., Nackaerts, K. L., Lerut, T. E. and Demedts, M. G. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Leuven lung cancer group. Ann. Thorac. Surg., 63, 1441-1450 (1997).
4. Naruke, T., Goya, T., Tsuchiya, R. and Suemasu, K. The importance of surgery to non-small cell carcinoma of lung with mediastinal lymph node metastasis. Ann. Thorac. Surg., 46, 603-610 (1988).
5. Watanabe, Y., Hayashi, Y., Shimizu, J., Oda, M. and Iwa, T. Mediastinal nodal involvement and the prognosis of non-small cell lung cancer. Chest, 100, 422-428 (1991).
6. Maggi, G., Casadio, C., Cianci, R., Molinatti, M., Filosso, P. L., Nicolosi, M. and Oliaro, A. Results of surgical resection of stage IIIa (N2) non small cell lung cancer, according to the site of the mediastinal metastases. Int. Surg., 78, 213-217 (1993).
7. Yano, S. and Sone, S. Novel metastasis model of human lung cancer cells representing different histological types in SCID mice depleted of NK cells. Jpn. J. Cancer Chem., 24, 489-494 (1997).
8. Mclemore, T. L., Liu, M. C., Blacker, P. C., Gregg, M., Alley, M. C., Abbott, B. J., Shoemaker, R. H., Bohlman, M. E., Litterst, C. C., Hubbard, W. C., Robert, H. B., James, B. M., Donald, L. F., Joseph, C. E., Joseph, G. M. and Michael, R. B. Novel intrapulmonary model for orthotopic propagation of human lung cancers in athymic nude mice. Cancer Res., 47, 5132-5140 (1987).
9. Howard, R. B., Chu, H., Zeligman, B. E., Marcell, T., Bunn, P. A., Mclemore, T. L., Mulvin, D. W., Cowen, M. E. and Johnston, M. R. Irradiated nude rat model for orthotopic human lung cancers. Cancer Res., 51, 3274-3280 (1991).
10. Doki, Y., Murakami, K., Yamaura, T., Sugiyama, S., Misaki, T. and Saiki, I. Mediastinal lymph node metastasis model by orthotopic intrapulmonary implantation of Lewis lung carcinoma cells in mice. Br. J. Cancer, 79, 1121-1126 (1999).
11. Murakami, K., Wierzba, K., Sano, M., Shibata, J., Yonekura, K., Hashimoto, A., Sato, K. and Yamada, Y. TAC-101, a benzoic acid derivative, inhibits liver metastasis of human gastrointestinal cancer and prolongs the lifespan. Clin. Exp. Metastasis, 16, 323-331 (1998).
12. Lee, J. S., Favre, B., Hemmings, B. A., Kiefer, B. and Nagamine, Y. Okadaic acid-dependent induction of the urokinase-type plasminogen activator gene associated with stabilization and autoregulation of c-Jun. J. Biol. Chem., 269, 2887-2894 (1994).
13. Lengyel, E., Stepp, E., Gum, R. and Boyd, D. Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras. J. Biol. Chem., 270, 23007-23012 (1995).
14. De Cesare, D., Palazzolo, M. and Blasi, F. Functional characterization of COM, a DNA region required for cooperation between AP-1 sites in urokinase gene transcription. Oncogene, 13, 2551-2562 (1996).
15. Janulis, M., Silberman, S., Ambegaokar, A., Gutkind, J. S. and Schultz, R. M. Role of mitogen-activated protein kinases and c-Jun/AP-1 trans-activating activity in the regulation of protease mRNAs and the malignant phenotype in NIH 3T3 fibroblasts. J. Biol. Chem., 274, 801-813 (1999).
16. Ried, S., Jager, C., Jeffers, M., Vande Woude, G. F., Graeff, H., Schmitt, M. and Lengyel, E. Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor. J. Biol. Chem., 274, 16377-16386 (1999).
17. Livingston, R. B. Combined modality therapy of lung cancer. Clin. Cancer Res., 3, 2638-2647 (1997).
18. Rigas, J. R. Do newer chemotherapeutic agents improve survival in non-small cell lung cancer? Semin. Oncol., 25, 5-9 (1998).
19. Nomura, T., Sakurai, Y. and Inaba, M. In "The Nude Mouse and Anticancer Drug Evaluation," ed. T. Nomura, Y. Sakurai and M. Inaba, pp. 29-52 (1996). Jpn. J. Cancer and Chemotherapy Publishers Inc., Tokyo.
20. Saito, K., Ata, N., Miyashiro, H., Hattori, M. and Saiki, I. A modified and convenient method for assessing tumor cell invasion and migration and its application to screening for inhibitors. Biol. Pharm. Bull., 20, 345-348 (1997).
21. Matsuo, O., Sakai, T., Bando, H., Okada, K., Nakajima, S., Takagi, O. and Izaki, S. Plasminogen activator in bronchoalveolar fluid. Haemostasis, 16, 43-50 (1986).
22. Yang, J. N., Allan, E. H., Anderson, G. I., Martin, T. J. and Minkin, C. Plasminogen activator system in osteoclasts. J. Bone Miner. Res., 12, 761-768 (1997).
23. Krzesicki, R. F., Winterrowd, G. E., Brashler, J. R., Hatfield, C. A., Griffin, R. L., Fidler, S. F., Kolbasa, K. P., Shull, K. L., Richards, I. M. and Chin, J. E. Identification of cytokine and adhesion molecule mRNA in murine lung tissue and isolated T cells and eosinophils by semi-quantitative reverse transcriptase-polymerase chain reaction. Am. J. Respir. Cell Mol. Biol., 16, 693-701 (1997).
24. McArdle, B. H. The significance of differences between means. A simulation study. Comp. Biochem. Physiol., 87, 979-982 (1987).
25. Hilton, J. F. The appropriateness of the Wilcoxon test in ordinal data. Stat. Med., 30, 631-645 (1996).
26. Hochberg, Y. and Tamhane, A. C. Multivariate t-distribution. In "Multiple Comparison Procedures," ed. Y. Hochberg and A. C. Tamhane, pp. 374-375 (1987). John Wiley & Sons, New York.
27. Maurer, W., Hothorn, L. A. and Lehmacher, W. Multiple comparisons in drug clinical trials and preclinical assays: a-priori ordered hypothesis. Biomed. Chem.-Pharm. Ind., 6, 3-18 (1995).
28. Kobayashi, H., Gotoh, J., Fujie, M., Shinohara, H., Moniwa, N. and Terao, T. Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int. J. Cancer, 57, 727-733 (1994).
29. Tanaka, N., Ogawa, H., Tanaka, K., Kinjo, M. and Kohga, S. Effects of tranexamic acid and urokinase on hematogenous metastases of Lewis lung carcinoma in mice. Invasion Metastasis, 1, 149-157 (1981).
30. Kobayashi, H., Gotoh, J., Shinohara, H., Moniwa, N. and Terao, T. Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model. Thromb. Haemost., 71, 474-480 (1994).
31. Matsumoto, H., Ueshima, S., Fukao, H., Mitsui, Y. and Matsuo, O. Effects of lipopolysaccharide on the expression of fibrinolytic factors in an established cell line from human endothelial cells. Life Sci., 59, 58-96 (1996).
32. Lengyel, E., Wang, H., Stepp, E., Juarez, J., Wang, Y., Doe, W., Pfarr, C. M. and Boyd, D. Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene. J. Biol. Chem., 271, 23176-23184 (1996).
33. Andreasen, P. A., Kjoller, L., Christensen, L. and Duffy, M. J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer, 72, 1-22 (1997).
34. Reuning, U., Magdolen, V., Wilhelm, O., Fischer, K., Lutz, V., Graeff, H. and Schmitt, M. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Int. J. Oncol., 13, 893-906 (1998).
35. Morita, S., Sato, A., Hayakawa, H., Ihara, H., Urano, T., Takada, Y. and Takada, A. Cancer cells overexpress mRNA of urokinase-type plasminogen activator, its receptor and inhibitors in human non-small-cell lung cancer tissue: analysis by Northern blotting and in situ hybridization. Int. J. Cancer, 78, 286-292 (1998).
36. Oka, T., Ishida, T., Nishino, T. and Sugimachi, K. Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma. Cancer Res., 51, 3522-3525 (1991).
37. Nagayama, M., Sato, A., Hayakawa, H., Urano, T., Takada, Y. and Takada, A. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination. Cancer, 73, 1398-1405 (1994).
38. Volm, M., Drings, P. and Wodrich, W. Prognostic significance of the expression of c-fos, c-jun and c-erbB-1 oncogene products in human squamous cell lung carcinomas. J. Cancer Res. Clin. Oncol., 119, 507-510 (1993).
39. Volm, M., van, Kaick, G. and Mattern, J. Analysis of c-fos, c-jun, c-erbB1, c-erbB2 and c-myc in primary lung carcinomas and their lymph node metastases. Clin. Exp. Metastasis, 12, 329-334 (1994).
40. Frisch, S. M. and Morisaki, J. H. Positive and negative transcriptional elements of the human type IV collagenase gene. Mol. Cell. Biol., 10, 6524-6532 (1990).
41. Domann, F. E., Levy, J. P., Birrer, M. J. and Bowden, G. T. Stable expression of a c-JUN deletion mutant in two malignant mouse epidermal cell lines blocks tumor formation in nude mice. Cell Growth Differ., 5, 9-16 (1994).
42. Vansteenkiste, J. F., De Leyn, P. R., Deneffe, G. J., Stalpaert, G., Nackaerts, K. L., Lerut, T. E. and Demedts, M. G. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Leuven Lung Cancer Group. Ann. Thorac. Surg., 63, 1441-1450 (1997).
43. Dumler, I., Kopmann, A., Weis, A., Mayboroda, O. A., Wagner, K., Gulba, D. C. and Haller, H. Urokinase activates the Jak/Stat signal transduction pathway in human vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol., 19, 290-297 (1999).